Celgene Co. (CELG) Shares Sold by Man Group plc

Man Group plc decreased its holdings in shares of Celgene Co. (NASDAQ:CELG) by 79.7% during the third quarter, Holdings Channel reports. The fund owned 317,177 shares of the biopharmaceutical company’s stock after selling 1,244,592 shares during the period. Man Group plc’s holdings in Celgene were worth $28,384,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. Lucia Wealth Services LLC acquired a new stake in shares of Celgene during the third quarter worth about $243,000. MUFG Americas Holdings Corp lifted its holdings in shares of Celgene by 22.9% during the third quarter. MUFG Americas Holdings Corp now owns 113,323 shares of the biopharmaceutical company’s stock worth $10,142,000 after purchasing an additional 21,138 shares during the period. Pacer Advisors Inc. lifted its holdings in shares of Celgene by 19.1% during the third quarter. Pacer Advisors Inc. now owns 67,459 shares of the biopharmaceutical company’s stock worth $6,037,000 after purchasing an additional 10,802 shares during the period. Paloma Partners Management Co lifted its holdings in shares of Celgene by 109.1% during the third quarter. Paloma Partners Management Co now owns 146,865 shares of the biopharmaceutical company’s stock worth $13,143,000 after purchasing an additional 76,617 shares during the period. Finally, Highland Capital Management LP acquired a new stake in shares of Celgene during the third quarter worth about $2,201,000. Institutional investors and hedge funds own 72.87% of the company’s stock.

Shares of CELG stock opened at $68.20 on Friday. The company has a debt-to-equity ratio of 4.06, a current ratio of 2.13 and a quick ratio of 1.99. The company has a market cap of $47.69 billion, a PE ratio of 9.97, a price-to-earnings-growth ratio of 0.42 and a beta of 1.50. Celgene Co. has a 1-year low of $66.62 and a 1-year high of $110.20.

Celgene (NASDAQ:CELG) last announced its earnings results on Thursday, October 25th. The biopharmaceutical company reported $2.29 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.02 by $0.27. The business had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.83 billion. Celgene had a return on equity of 108.76% and a net margin of 19.64%. On average, sell-side analysts forecast that Celgene Co. will post 7.45 earnings per share for the current fiscal year.

A number of equities research analysts recently commented on CELG shares. BidaskClub downgraded Celgene from a “buy” rating to a “hold” rating in a report on Thursday, September 13th. Zacks Investment Research downgraded Celgene from a “buy” rating to a “hold” rating in a report on Wednesday, September 26th. Cantor Fitzgerald initiated coverage on Celgene in a report on Monday, October 1st. They issued an “overweight” rating and a $100.00 price target for the company. JPMorgan Chase & Co. reissued a “buy” rating on shares of Celgene in a report on Thursday, October 11th. Finally, Leerink Swann set a $112.00 price target on Celgene and gave the company a “hold” rating in a report on Friday, October 26th. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. Celgene presently has a consensus rating of “Buy” and an average target price of $116.99.

ILLEGAL ACTIVITY NOTICE: “Celgene Co. (CELG) Shares Sold by Man Group plc” was originally reported by Markets Daily and is owned by of Markets Daily. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.themarketsdaily.com/2018/12/16/celgene-co-celg-shares-sold-by-man-group-plc.html.

Celgene Profile

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Featured Story: How Investors Use a Balance Sheet

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply